Identification of novel cancer-specific antigens and application for cellular imunotherapy of hematological malignancies

新型癌症特异性抗原的鉴定及其在血液恶性肿瘤细胞免疫治疗中的应用

基本信息

  • 批准号:
    13470206
  • 负责人:
  • 金额:
    $ 8.83万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
  • 财政年份:
    2001
  • 资助国家:
    日本
  • 起止时间:
    2001 至 2002
  • 项目状态:
    已结题

项目摘要

To identify the novel cancer-associated antigens and to develop the novel immunotherapy for hematological malignancies, this study was performed. The data obtained from the series of experiments are as follows.1) A WT1-specific, HLA-A24-restricted CTL clone (designated TAK-1) exhibited cytotoxicity against lung cancer cell lines bearing HLA-A24 but did not lyse cells lacking this HLA. Adoptive transfer of TAK-1 into nude mice that had been engrafted with an HLA-A24-positive lung cancer cell line resulted in inhibition of the cancer cell growth and prolonged survival. These findings strongly suggest that WT1 is a universal tumor-associated antigen and that WT1 -targeting immunotherapy offers a potentially effective treatment option for lung cancer as well as leukemia.2) A novel WT1-derived peptide-specific CD8^+ CTL line, designated NIM-1 was established. NIM-1 lysed HLA-A24-positive leukaemia cells, but not HLA-A24 negative leukaemia cells or normal cells.3) Immature dendritic cells (D … More Cs) were loaded with leukemia cells with t(6 ; 9) or t(9 ; 22) and then cocultured with the dek-can fusion peptide-specific or the bcr-abl fusion peptide-specific CD4^+ T-lymphocyte clone. The dek-can peptide-specific and bcr-abl peptide-specific CD4^+ T-lymphocyte clones produced interferon-γ(IFN-γ) when they were cocultured with HLA-DR-matched but not with mismatched DCs which had been loaded with apoptotic as well as necrotic leukemia cells with t(6 ; 9) and t(9 ; 22), respectively. These data indicate that the acute myelogenous leukemia-associated fusion protein, dek-can, and chronic myelogenous leukemia-associated fusion protein, bcr-abl, are both processed and presented by DCs to the fusion peptide-specific CD4^+ T lymphocytes.4) In order to clarify the roles of perforin in antigen-specific cytotoxicity mediated by human CD4^+ CTLs, antigen-specific human CD4^+ T-lymphocyte clones were established from a patient with hereditary perforin deficiency and their cytotoxic activities were investigated. The data demonstrated that perforin-negative CD4^+ CTLs can exert cytotoxicity against Fas-sensitive target cells ; however, perforin plays essential roles in antigen-specific cytotoxicity mediated by human CD4^+ as well as CD8^+ CTLs. Less
本研究旨在寻找新的肿瘤相关抗原,为恶性血液病的免疫治疗提供新的思路。从一系列实验中获得的数据如下:1)WT 1特异性、HLA-A24限制性CTL克隆(命名为TAK-1)对携带HLA-A24的肺癌细胞系表现出细胞毒性,但不裂解缺乏该HLA的细胞。将TAK-1连续转移至已植入HLA-A24阳性肺癌细胞系的裸鼠体内,可抑制癌细胞生长并延长存活期。这些发现有力地表明WT 1是一种通用的肿瘤相关抗原,并且WT 1靶向免疫治疗为肺癌和白血病提供了一种潜在有效的治疗选择。2)建立了一种新的WT 1衍生肽特异性CD 8 ^+ CTL细胞系,命名为NIM-1。NIM-1裂解HLA-A24阳性白血病细胞,但不裂解HLA-A24阴性白血病细胞或正常细胞 ...更多信息 Cs)分别负载t(6 ; 9)或t(9 ; 22)白血病细胞,然后与dek-can融合肽特异性或bcr-abl融合肽特异性CD 4 ^+ T淋巴细胞克隆共培养。当dek-can肽特异性和bcr-abl肽特异性CD 4 ^+ T淋巴细胞克隆与HLA-DR匹配的DC共培养时,它们产生干扰素-γ(IFN-γ),而与不匹配的DC共培养时,则不产生干扰素-γ(IFN-γ),而不匹配的DC分别负载了t(6 ; 9)和t(9 ; 22)的凋亡和坏死白血病细胞。这些数据表明,急性髓细胞白血病相关融合蛋白dek-can和慢性髓细胞白血病相关融合蛋白bcr-abl均被DC加工并提呈给融合肽特异性CD 4 ^+ T淋巴细胞。4)为了阐明穿孔素在人CD 4 ^+ CTL介导的抗原特异性细胞毒性中的作用,从遗传性穿孔素缺乏症患者中建立了抗原特异性人CD 4 ^+ T淋巴细胞克隆,并研究了它们的细胞毒活性。这些数据表明,穿孔素阴性的CD 4 ^+ CTL可以对Fas敏感的靶细胞产生细胞毒性;然而,穿孔素在由人CD 4 ^+和CD 8 ^+ CTL介导的抗原特异性细胞毒性中起着重要作用。少

项目成果

期刊论文数量(48)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Azuma, T., et al.: "Identification of a novel WT1-derived peptide which induces HLA-A24-restricted anti-leukaemia cytotoxic T lymphocytes"British Journal of Haematology. 116. 601-603 (2002)
Azuma,T.,等人:“诱导 HLA-A24 限制性抗白血病细胞毒性 T 淋巴细胞的新型 WT1 衍生肽的鉴定”英国血液学杂志。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Arai, J., et al.: "Identification of human telomerase reverse transcriptase-derived peptides which induce HLA-A24-restiricted antileukemia CTLs"Blood. 97. 2903-2907 (2001)
Arai, J. 等人:“诱导 HLA-A24 限制性抗白血病 CTL 的人端粒酶逆转录酶衍生肽的鉴定”血液。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Kakimoto, M., Hasegawa, A., Fujita, S. and Yasukawa, M.: "Phenotypic and functional alterations of dendritic cells induced by human herpesvirus 6 infection"J.Virol.. 76. 10338-10345 (2002)
Kakimoto, M.、Hasekawa, A.、Fujita, S. 和 Yasukawa, M.:“人疱疹病毒 6 感染诱导的树突状细胞的表型和功能改变”J.Virol.. 76. 10338-10345 (2002)
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Hasegawa, A., et al.: "Transcriptional down-regulation of CXCR4 induced by impaired association of YY1 with c-Myc in HHV-6-infected cells"Journal of Immunology. 166. 1125-1131 (2001)
Hasekawa, A. 等人:“HHV-6 感染细胞中 YY1 与 c-Myc 的关联受损导致 CXCR4 转录下调”《免疫学杂志》。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Makita, M., Yasukawa, M.et al.: "Antilung cancer effect of WT1-specific cytotoxic T lymphocytes"Clinical Cancer Research. 8. 2626-2613 (2002)
Makita, M., Yasukawa, M.等人:“WT1特异性细胞毒性T淋巴细胞的抗肺癌作用”临床癌症研究。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

YASUKAWA Masaki其他文献

Menin plays an critical role in the survival of antigen-specific activated CD8+ T cells
Menin 在抗原特异性激活的 CD8 T 细胞的存活中发挥着关键作用
  • DOI:
  • 发表时间:
    2015
  • 期刊:
  • 影响因子:
    0
  • 作者:
    YAMADA Takeshi;KANOH Makoto;MATSUMOTO Akira;YASUOKA Toshiaki;SUZUKI Junpei;MARUYAMA Saho;KUWAHARA Makoto;YASUKAWA Masaki;YAMASHITA Masakatsu
  • 通讯作者:
    YAMASHITA Masakatsu
A tumor suppressor Menin controls CD8 T cell senescence by regulating glutamine metabolism
肿瘤抑制因子 Menin 通过调节谷氨酰胺代谢来控制 CD8 T 细胞衰老
  • DOI:
  • 发表时间:
    2016
  • 期刊:
  • 影响因子:
    0
  • 作者:
    SUZUKI Junpei;KUWAHARA;Makoto;YASUKAWA Masaki;YAMASHITA Masakatsu
  • 通讯作者:
    YAMASHITA Masakatsu
The tumor suppressor menin epigenetically regulates CD8 T cell senescence via the modulation of glutamine metabolism
肿瘤抑制蛋白 menin 通过调节谷氨酰胺代谢从表观遗传学角度调节 CD8 T 细胞衰老
  • DOI:
  • 发表时间:
    2017
  • 期刊:
  • 影响因子:
    0
  • 作者:
    SUZUKI Junpei;KUWAHARA Makoto;YAMADA Takeshi;YASUKAWA Masaki;YAMASHITA Masakatsu
  • 通讯作者:
    YAMASHITA Masakatsu

YASUKAWA Masaki的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('YASUKAWA Masaki', 18)}}的其他基金

Development of the novel gene-immunotherapy using artificial CTL targeting leukemia stem cells
使用人工CTL靶向白血病干细胞开发新型基因免疫疗法
  • 批准号:
    24390245
  • 财政年份:
    2012
  • 资助金额:
    $ 8.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of a novel cancer therapy using soluble T-cell receptor
使用可溶性 T 细胞受体开发新型癌症疗法
  • 批准号:
    23659489
  • 财政年份:
    2011
  • 资助金额:
    $ 8.83万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Development of cancer immunotherapy using co-transfer of cancer-specific TCR gene and chemokine receptor gene
利用癌症特异性TCR基因和趋化因子受体基因共转移开发癌症免疫疗法
  • 批准号:
    21390294
  • 财政年份:
    2009
  • 资助金额:
    $ 8.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Novel hematopoietic stem cell transplantation using cancer-specific T-cell receptor gene transfer
使用癌症特异性 T 细胞受体基因转移的新型造血干细胞移植
  • 批准号:
    19390265
  • 财政年份:
    2007
  • 资助金额:
    $ 8.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of novel immunogene therapy for hamatopietic malignancies
造血系统恶性肿瘤新型免疫基因疗法的开发
  • 批准号:
    17390278
  • 财政年份:
    2005
  • 资助金额:
    $ 8.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Novel immunogene therapy for hematopoietic malignancies
造血系统恶性肿瘤的新型免疫基因疗法
  • 批准号:
    15390301
  • 财政年份:
    2003
  • 资助金额:
    $ 8.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of novel immunogene therapy for hematological malignancies
血液系统恶性肿瘤新型免疫基因疗法的开发
  • 批准号:
    12557081
  • 财政年份:
    2000
  • 资助金额:
    $ 8.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Immunogene therapy of cancer and virus infections using immortalized T-cell clones
使用永生化 T 细胞克隆对癌症和病毒感染进行免疫基因治疗
  • 批准号:
    11670449
  • 财政年份:
    1999
  • 资助金额:
    $ 8.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular analysis of new herpesvirusinfections
新疱疹病毒感染的分子分析
  • 批准号:
    09670477
  • 财政年份:
    1997
  • 资助金额:
    $ 8.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Abnormality of signal Transduction via T-cell receptors mediated by retrovirus infection
逆转录病毒感染介导的T细胞受体信号转导异常
  • 批准号:
    02670283
  • 财政年份:
    1990
  • 资助金额:
    $ 8.83万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)

相似海外基金

Optimizing the Efficacy and Safety of CD33-Targeted Immunotherapy for Acute Myeloid Leukemia and Other CD33+ Disorders
优化 CD33 靶向免疫疗法治疗急性髓系白血病和其他 CD33 疾病的疗效和安全性
  • 批准号:
    10733379
  • 财政年份:
    2023
  • 资助金额:
    $ 8.83万
  • 项目类别:
Myeloid cell-selective, oligonucleotide-based STAT3 inhibition combined with total marrow and lymphoid irradiation for immunotherapy of acute myeloid leukemia
骨髓细胞选择性、基于寡核苷酸的 STAT3 抑制联合全骨髓和淋巴照射用于急性髓系白血病的免疫治疗
  • 批准号:
    10752538
  • 财政年份:
    2023
  • 资助金额:
    $ 8.83万
  • 项目类别:
A systems glycobiology platform for revealing new immunotherapy targets in acute myeloid leukemia
用于揭示急性髓系白血病新免疫治疗靶点的系统糖生物学平台
  • 批准号:
    488516
  • 财政年份:
    2023
  • 资助金额:
    $ 8.83万
  • 项目类别:
    Operating Grants
Natural Killer (NK) Cell Immunotherapy Towards Adult T Cell Leukemia (ATL) via Exaltation of MICA/B Expression and Augments NK Cytotoxicity
通过提高 MICA/B 表达和增强 NK 细胞毒性来治疗成人 T 细胞白血病 (ATL) 的自然杀伤 (NK) 细胞免疫疗法
  • 批准号:
    22K16327
  • 财政年份:
    2022
  • 资助金额:
    $ 8.83万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Adoptive immunotherapy for adult T-cell leukemia/lymphoma with ex vivo expanded multi-tumor associated antigen specific cytotoxic T-cells
使用离体扩增的多肿瘤相关抗原特异性细胞毒性 T 细胞对成人 T 细胞白血病/淋巴瘤进行过继免疫治疗
  • 批准号:
    20K17375
  • 财政年份:
    2020
  • 资助金额:
    $ 8.83万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Map Leukemia-immune Cell Talks with Nanoplasmon Ruler in CAR T-Cell Immunotherapy
在 CAR T 细胞免疫疗法中使用 Nanoplasmon Ruler 绘制白血病免疫细胞对话图
  • 批准号:
    10407037
  • 财政年份:
    2020
  • 资助金额:
    $ 8.83万
  • 项目类别:
Gut microbiota analysis in cancer immunotherapy for refractory acute lymphoblastic leukemia in children
儿童难治性急性淋巴细胞白血病癌症免疫治疗中的肠道微生物群分析
  • 批准号:
    20K16864
  • 财政年份:
    2020
  • 资助金额:
    $ 8.83万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Map Leukemia-immune Cell Talks with Nanoplasmon Ruler in CAR T-Cell Immunotherapy
在 CAR T 细胞免疫疗法中使用 Nanoplasmon Ruler 绘制白血病免疫细胞对话图
  • 批准号:
    10657574
  • 财政年份:
    2020
  • 资助金额:
    $ 8.83万
  • 项目类别:
Map Leukemia-immune Cell Talks with Nanoplasmon Ruler in CAR T-Cell Immunotherapy
在 CAR T 细胞免疫疗法中使用 Nanoplasmon Ruler 绘制白血病免疫细胞对话图
  • 批准号:
    10059324
  • 财政年份:
    2020
  • 资助金额:
    $ 8.83万
  • 项目类别:
Map Leukemia-immune Cell Talks with Nanoplasmon Ruler in CAR T-Cell Immunotherapy
在 CAR T 细胞免疫疗法中使用 Nanoplasmon Ruler 绘制白血病免疫细胞对话图
  • 批准号:
    10159877
  • 财政年份:
    2020
  • 资助金额:
    $ 8.83万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了